CC
TEVA icon

Colrain Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Colrain Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-113,896
Closed -$3.78M – 60
2017
Q2 		$3.78M Sell
113,896
-34,950
-23% -$1.08M 1.54% 29
2017
Q1 		$4.78M Sell
148,846
-100,304
-40% -$3.42M 1.44% 27
2016
Q4 		$9.03M Sell
249,150
-110,100
-31% -$4.4M 1.89% 21
2016
Q3 		$16.5M Sell
359,250
-44,325
-11% -$2.31M 3.73% 4
2016
Q2 		$20.3M Sell
403,575
-17,750
-4% -$945K 4.04% 3
2016
Q1 		$22.5M Sell
421,325
-139,175
-25% -$8.17M 3.92% 3
2015
Q4 		$36.8M Buy
560,500
+143,100
+34% +$8.84M 3.73% 7
2015
Q3 		$23.6M Buy
+417,400
New +$27.1M 2.46% 21
2015
Q1 		– Sell
-6,000
Closed -$345K – 103
2014
Q4 		$345K Sell
6,000
-9,000
-60% -$501K 0.03% 81
2014
Q3 		$806K Sell
15,000
-2,500
-14% -$132K 0.06% 75
2014
Q2 		$917K Buy
17,500
+2,500
+17% +$128K 0.07% 78
2014
Q1 		$793K Sell
15,000
-17,500
-54% -$809K 0.06% 76
2013
Q4 		$1.3M Buy
32,500
+18,500
+132% +$728K 0.09% 73
2013
Q3 		$529K Sell
14,000
-13,500
-49% -$527K 0.04% 83
2013
Q2 		$1.08M Buy
+27,500
New +$1.07M 0.08% 74

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Colrain Capital's TEVA Position: Q3 2017 in Review

Colrain Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 113,896 shares — an estimated $3.78M sold.

Colrain Capital first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $36.8M in Q4 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Colrain Capital reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Colrain Capital sold 113,896 Teva Pharmaceuticals shares in Q3 2017, an estimated $3.78M.
  • Colrain Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Colrain Capital's Teva Pharmaceuticals position peaked at $36.8M in Q4 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Colrain Capital's 13F filing for Q3 2017, filed 2 Nov 2017.